#JPM23: Fire­side chat with Ei­sai's Ivan Che­ung

Less than a week af­ter Ei­sai and Bio­gen won ac­cel­er­at­ed ap­proval from the FDA for their Alzheimer’s drug lecanemab, Ex­ec­u­tive Ed­i­tor Drew Arm­strong spoke one-on-one with Ei­sai’s US CEO Ivan Che­ung, who al­so leads the com­pa­ny’s Alzheimer’s ef­forts. This tran­script has been edit­ed for brevi­ty and clar­i­ty.

Drew Arm­strong:

Wel­come every­body. I am Drew Arm­strong, the ex­ec­u­tive ed­i­tor over at End­points News, and I’m ex­cep­tion­al­ly pleased to be joined by Ivan Che­ung from Ei­sai. He runs the US busi­ness and over­sees the Alzheimer’s pro­gram there. Ob­vi­ous­ly, you all have had some enor­mous news in the last week with the ac­cel­er­at­ed ap­proval of Lecanemab, and con­grat­u­la­tions on that. It’s ob­vi­ous­ly a huge mo­ment for the field, huge mo­ment for your com­pa­ny. I want to jump right in be­cause we have 30 min­utes and so much to cov­er. I’m in­cred­i­bly ex­cit­ed to get this chance to talk to you. Now, that I’m in San Fran­cis­co, you’re in New Jer­sey. I’m sor­ry we aren’t able to be to­geth­er in per­son, but tons of news from you all. You’ve got­ten this ac­cel­er­at­ed ap­proval.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN